AMiNDR: A Month in Neurodegenerative Disease Research

Naila is back to round off our risk factors section with an episode on genome-wide association studies, transcriptomic research, combining genetics and neuroimaging data, and new tools to make all this work easier. Tune in to learn more about the techniques used to study the genetic underpinnings of AD, and perhaps to learn some long gene names to impress people at the next party you attend - espe...

With over 700km of blood vessels in the brain, it’s no surprise that brain and vascular health are closely related. In this episode, Elyn takes you through papers published in August 2020 on cerebrovascular changes in AD. Tune in to learn more about amyloid clearance, platelet aggregation, and changes in the neurovascular unit over the course of the disease. ---------------------------------------...

Today’s episode is all about Diagnostic Tools and Imaging papers published in August 2020. As you will soon see, these papers explore a wide range of topics including potential biomarkers of AD, hormone markers and EEG analyses. While these papers didn’t quite fit into some of the other diagnostic tools and Imaging subthemes discussed in previous and upcoming episodes (such cognitive testing, imag...

n this episode, Alex will be covering papers published in August 2020 within the category of novel drug development, that focus on multi-targeted approaches to Alzheimer’s disease treatment, and a few papers that don’t quite fit under any of the themes we’ve covered so far. We’ll take a look at studies targeting many different AD processes, including oxidative stress, cholinesterase activity, and...

Naila covers a wide variety of biomarkers and topics from papers published in August 2020 on Alzheimer's disease: identifying biomarkers of cognition and memory in cognitively unimpaired older adults, biomarkers that can help predict AD progression and differentiation, new biomarker assays and tools for improved diagnosis, EEG, metabolic profiling...  ----------------------------------------------...

In this episode, Marcia talks about papers published in August 2020 within the novel drug development category that focus on targeting tau, the cholinergic system, mitochondria, metabolism and the immune system, as a way to combat Alzheimer's Disease. Check out episode 56 for the first part, where you'll hear more on novel drug development targeting Amyloid-beta production, aggregation, and toxici...

Judy covers the second half of papers released in August 2020 on amyloid or tau protein detection in the brain. This selection features mouse models, machine learning, mass spectrometry and other cool methods to detect these biomarkers of Alzheimer’s disease. Check episode 39 for the first part. We hope you find this episode useful and accessible. --------------------------------------------------...

Today we have another episode focused on the latest findings in Alzheimer’s disease blood biomarkers research, where Elyn covers abstracts from papers published in August 2020. These papers were clumped together based on the fact that they all focused on measuring something in the blood to either predict or diagnose Alzheimer disease – making them blood biomarkers! In this episode, you’ll hear abo...

Feeling PERK-y? An eclectic assortment of papers that address Alzheimer’s disease mechanisms in various ways awaits you in this episode. Anusha Kamesh will be guiding your journey through papers released in August of 2020 that concern metabolism, mitochondrial function, oxidative stress, autophagy, and gut microbiome ------------------------------------------------------------------  To receive th...

Marcia will tell you about papers published in August 2020 within the Novel drug development category that focus on all things Amyloid-beta. She will cover research focussed on targeting Amyloid-beta production, aggregation, and toxicity, as a way to combat AD. ------------------------------------------------------------------  To receive the list of papers covered, please fill this form:   ------...

We may not have a disease-modifying agent for Alzheimer’s disease yet, but there are several approved medications that can help slow down the progression of the disease. Can we improve these medications and make them more potent? Are there different ways we can administer them to improve their efficacy? And while we are talking about approved medications, are there any hidden gems on the market th...

In this episode, Alex covers the latest research involving CSF biomarkers as a critical diagnostic tool in Alzheimer’s Disease identification and treatment. You’ll hear about some of the more typical clinical CSF biomarkers seen in AD, as well as the signature CSF AD biomarker profile, and you’ll also learn about how some of these CSF  biomarkers relate to the different stages of AD progression an...

In this episode, Courtney will update you on papers published in August 2020 on the genetic landscapes of ApoE. You will hear about models of ApoE, ethnic variability in ApoE, clinical implications of ApoE, and even some molecular mechanisms of ApoE. ------------------------------------------------------------------  To receive the list of papers covered, please fill this form:   -------->  https:...

What role does social media play in academia and science communication nowadays? How can we keep our biases from interfering with fair reporting and objective coverage? Do we need to revise our inclusion criteria for the papers we cover? How relevant is the categorization of research by disease when there is so much overlap in underlying mechanisms? And how much responsibility do we hold through o...

Ellen tells you about the latest papers on cognitive testing for AD and mild cognitive impairment! This includes papers that delve deeper into how cognition is affected in AD and other disorders, and in some cases compare these changes to neurological data. Other papers validate existing cognitive assessment tools, or describe brand new ones, including new analysis algorithms and computer-based te...

Listen to Jacques as he recites tongue-twisters and updates you on the latest papers on amyloid-beta aggregation and toxicity in AD from August, 2020! We hope you like the episode, and if you're interested in amyloid pathology in AD, you might want to check out Jacques' last episode as well, episode 47 on APP processing.  ------------------------------------------------------------------  To recei...

The genetic landscape of Alzheimer's disease can be overwhelmingly broad. In this episode, Joseph is back to tell you about peer-reviewed research dealing with epigenetics, non-APOE related genetic pathways and a couple new genetic models that have been published in August 2020. Enjoy!  ------------------------------------------------------------------  To receive the list of papers covered, pleas...

Join Anusha as she dives into papers published from August of 2020 that uncovers the effects of potential therapeutics in animal models for Alzheimer's Disease. In the first section, she covers research that targets multiple aspects of Alzheimer's pathology. In the second section, she focuses on research that aims to improve cognition and memory in animal models.  ---------------------------------...

In this episode, Jacques updates you on the newest papers related to amyloid precursor protein processing in AD! You'll hear about the gamma secretase complex, the influence of accessory proteins on amyloidogenic cleavages of APP, and  APP glycosylation patterns, among other interesting topics! Enjoy.   ------------------------------------------------------------------  To receive the list of pape...

Bhumika is back to tell you more about the latest tools and techniques in imaging to diagnosis Alzheimer's disease from papers published in August 2020. This includes PET imaging, MRI, and machine learning techniques. If you're interested in this topic, make sure to check out Part 1, which is episode 43, as well. Enjoy!  ------------------------------------------------------------------  To receiv...

In this episode, Naila takes you through peer-reviewed research published in August 2020, on the many non-pharmacological approaches to treating AD. She covers a lot of territory, from diet-based approaches, to exercise programs and their potential underlying mechanisms, to brain stimulation and some more esoteric treatments. This episode is sure to leave you with some food for thought.   --------...

You'll hear about some big topics in Alzheimer's disease research in this episode! Ellen covers all of the pre-clinical studies from August 2020 testing potential new treatments targeting neuroinflammation, oxidative stress, mitochondria, metabolism, and lipids. This is the second part of three pre-clinical testing episodes this month, check out episode #42 for part 1, and look out for part 3, com...

Bhumika updates you on the new papers that use brain imaging to diagnose and study AD, in the first of two episodes on this topic! This includes new advances in MRI and PET imaging, and machine learning approaches. You'll hear about studies that looked at changes to functional connectivity, cortical thickness, and other neurological changes in AD, as well as new and improved methods to analyze bra...

In Part 1 of the AD preclinical testing papers published in August 2020, Naila gets us started with some treatments that target the cholinergic system and synaptic function, tau phosphorylation and resulting pathology, and amyloid-beta mediated toxicity. Given these are some of the hallmarks of AD pathology, trying to prevent or reverse their effects could lead to promising therapeutic outcomes, w...

Heather covers papers from August 2020 on the role of neuroinflammation and glial cells on Alzheimer's disease pathology. You'll hear about many papers studying the role of astrocytes and microglia in AD pathology, including how they interact with cell signalling pathways and AD-associated proteins such as amyloid and tau. She ends with a couple papers that aim to understand and/or model neuroinfl...